Login / Signup

Revisiting MET: Clinical Characteristics and Treatment Outcomes of Patients with Locally Advanced or Metastatic, MET-Amplified Esophagogastric Cancers.

Surendra Pal ChaudharyEunice L KwakKatie L HwangJochen K LennerzRyan B CorcoranRebecca S HeistAndrea L RussoAparna ParikhDarrell R BorgerLawrence S BlaszkowskyJason E FarisJanet E MurphyChristopher G AzzoliEric J RoelandLipika GoyalJill AllenJohn T MullenDavid P RyanA John IafrateSamuel J KlempnerJeffrey W ClarkTheodore S Hong
Published in: The oncologist (2020)
This article describes 233 patients who received MET amplification testing and reports (a) a positivity rate of 12%, similar to the rate of HER2 positivity in this data set; (b) the clinical characteristics of poorly differentiated tumors and nodal metastases; and (c) markedly shorter progression-free survival and overall survival in MET-amplified tumors. Favorable outcomes are reported for patients treated with MET inhibitors. Given the lack of published data in MET-amplified esophagogastric cancers and the urgent clinical importance of identifying patients with MET amplification for MET-directed therapy, this large series is a valuable addition to the literature and will have an impact on future practice.
Keyphrases